FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210251569> ?p ?o ?g. }

• W4210251569 abstract "Pseudolymphoma of skin or cutaneous lymphoid hyperplasia (CLH) is an exaggerated immune response to different stimuli such as contact dermatitis, tattoos, infections, arthropod bites, exposure to drugs and in many instances is idiopathic.1CLH can resolve spontaneously or persist for a long time. Coronavirus disease (COVID-19) is a pandemic that leads to morbidity and mortality around world. Intravenous immunoglobulin (IVIG) had been used as an adjuvant therapy for COVID-19 pneumonia.2Herein, we present dramatic resolution of CLH after treatment for COVID-19 infection. An otherwise healthy 52-year-old woman presented with 1-year history of multiple asymptomatic red nodules on forehead and nasolabial area which gradually became larger and coalesced into large firm multinodular plaques on forehead. Skin biopsy show nodular infiltrate of lymphoid cells composed of small to medium-sized lymphocytes admixed with some histiocytes and plasma cells with vague lymphoid follicle morphology. Infiltrate extends in between follicular structures and deep dermis with an uninvolved Grenz zone undersurface of epidermis. Immunohistochemistry study reveals multiple immunoreactions of small lymphocytes for CD2, CD3, CD20, scattered reactivity for CD4, CD5, CD8, Bcl-2 and Bcl-6, and negative immunoreaction for CD21, CD23 (Figure 1). Ziehl-Neelsen stain, fungal cultures, polymerase chain reaction test for leishmania and mycobacteria, antinuclear antibody and rapid plasma reagin; were all negative. Chest, abdomen and pelvis computed tomography scan did not show any lymphadenopathy or mass. CLH was diagnosed and patient treated with intralesional corticosteroid and prednisolone 10 mg for 3 months without any response and she discontinued treatment. During COVID-19 pandemic in 2020, she was infected and hospitalized in intensive care unit and received intravenous fluid, supportive care and dexamethasone (8 mg/daily). After several days IVIG (Intratect®, Biotest AG, Dreieich, Germany) 1 g/kg was administered. Immediately after initiation of IVIG, CLH lesions started to resolve and almost complete resolution was observed within 2 weeks. After that, treatment for COVID-19 infection was continued using interferon-beta-1-a, ivermectin and favipiravir and patient survived without long term complications. She did not experience any recurrence of CLH lesions until 9 months later. Cutaneous lymphoid hyperplasia is a benign reactive lymphoproliferative disorder which resemble lymphoma clinically and histologically. In the case of known stimuli such as drug, contact dermatitis, bites and injections, cession of exposure is the mainstay of treatment. Infections should be treated with appropriate antibiotics or antiviral agents. Whenever causative factor cannot be detected or not responding to previous strategies, treatments such as topical, intralesional and systemic corticosteroids, tacrolimus, cryotherapy, surgery, laser, radiotherapy, systemic hydroxychloroquine is necessary.1, 3-5 Although there is not a consensus on systemic corticosteroid dosage, high dose systemic corticosteroid is reserved for patients with systemic symptoms. Limited skin lesions usually respond to topical or intralesional corticosteroids.4 Intravenous immunoglobulin is a blood product which contains IgG antibodies from thousands of healthy donors who have encountered various antigens. IVIG is used in treatment of autoimmune and inflammatory diseases.2 Mechanism of action is not fully understood but suppression of antibody production, blocking complement mediated effects, neutralization of pathogenic antibodies, downregulation of T-cell activation and blocking Fas ligand/Fas receptor interaction have been raised.6, 7 To the best of our knowledge, this is the first report of IVIG usage in treatment of CLH. Chronic antigenic stimulation along with immune dysregulation induce lymphocytic proliferation in CLH. An exaggerated immune response result from cellular damage by haptens, also play a role.4, 8 IVIG decrease lymphocytic proliferation and antibody formation, inhibit complement system function and restore immune balance. By mentioned mechanisms, IVIG can be effective in treatment of CLH. Despite, Johnson et al, reported a case of palpable migratory arciform erythema which is a rare form of cutaneous T-cell pseudolymphoma induced by IVIG.9 Our patient received IVIG in combination with dexamethasone; however, she was previously treated with systemic and intralesional corticosteroid without any response. We propose that IVIG acts as steroid-sparing agent and prescribing it along with systemic corticosteroids revert corticosteroid resistant state. In conclusion, IVIG can be considered in treatment of resistant and refractory cases of CLH as an immunomodulator agent. More studies should be done to confirm the efficacy of IVIG in CLH. The authors declare no conflict of interest. Conception and design, acquisition of data, revising the manuscript, given final approval: Kamran Balighi. Drafting the manuscript, analysis and interpretation of data: Mahshid Sadat Ansari. Acquisition of data: Behnam Hashemi Urimi. Analysis and interpretation of data: Alireza Ghanadan. Drafting the manuscript: Nasim Tootoonchi. Data available on request due to privacy/ethical restrictions. We have obtained the consent of patient to participate in this study. Data available on request due to privacy/ethical restrictions. We have obtained the consent of patient to participate in this study." @default.
• W4210251569 created "2022-02-08" @default.
• W4210251569 creator A5003550219 @default.
• W4210251569 creator A5032409328 @default.
• W4210251569 creator A5062292959 @default.
• W4210251569 creator A5080464508 @default.
• W4210251569 creator A5088052569 @default.
• W4210251569 date "2022-02-12" @default.
• W4210251569 modified "2023-09-26" @default.
• W4210251569 title "Dramatic resolution of cutaneous lymphoid hyperplasia after receiving intravenous immunoglobulin for <scp>COVID</scp> ‐19" @default.
• W4210251569 cites W2056025335 @default.
• W4210251569 cites W2103563370 @default.
• W4210251569 cites W2146353168 @default.
• W4210251569 cites W2769543413 @default.
• W4210251569 cites W2907025971 @default.
• W4210251569 cites W2951855787 @default.
• W4210251569 cites W2953792317 @default.
• W4210251569 cites W3012704879 @default.
• W4210251569 cites W3163315390 @default.
• W4210251569 doi "https://doi.org/10.1111/dth.15347" @default.
• W4210251569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35102649" @default.
• W4210251569 hasPublicationYear "2022" @default.
• W4210251569 type Work @default.
• W4210251569 citedByCount "1" @default.
• W4210251569 countsByYear W42102515692022 @default.
• W4210251569 crossrefType "journal-article" @default.
• W4210251569 hasAuthorship W4210251569A5003550219 @default.
• W4210251569 hasAuthorship W4210251569A5032409328 @default.
• W4210251569 hasAuthorship W4210251569A5062292959 @default.
• W4210251569 hasAuthorship W4210251569A5080464508 @default.
• W4210251569 hasAuthorship W4210251569A5088052569 @default.
• W4210251569 hasConcept C116675565 @default.
• W4210251569 hasConcept C138268822 @default.
• W4210251569 hasConcept C142724271 @default.
• W4210251569 hasConcept C154945302 @default.
• W4210251569 hasConcept C159047783 @default.
• W4210251569 hasConcept C159654299 @default.
• W4210251569 hasConcept C203014093 @default.
• W4210251569 hasConcept C2777562237 @default.
• W4210251569 hasConcept C2779134260 @default.
• W4210251569 hasConcept C2779338263 @default.
• W4210251569 hasConcept C2780117679 @default.
• W4210251569 hasConcept C2780898057 @default.
• W4210251569 hasConcept C3006700255 @default.
• W4210251569 hasConcept C3007834351 @default.
• W4210251569 hasConcept C3008058167 @default.
• W4210251569 hasConcept C41008148 @default.
• W4210251569 hasConcept C524204448 @default.
• W4210251569 hasConcept C71924100 @default.
• W4210251569 hasConceptScore W4210251569C116675565 @default.
• W4210251569 hasConceptScore W4210251569C138268822 @default.
• W4210251569 hasConceptScore W4210251569C142724271 @default.
• W4210251569 hasConceptScore W4210251569C154945302 @default.
• W4210251569 hasConceptScore W4210251569C159047783 @default.
• W4210251569 hasConceptScore W4210251569C159654299 @default.
• W4210251569 hasConceptScore W4210251569C203014093 @default.
• W4210251569 hasConceptScore W4210251569C2777562237 @default.
• W4210251569 hasConceptScore W4210251569C2779134260 @default.
• W4210251569 hasConceptScore W4210251569C2779338263 @default.
• W4210251569 hasConceptScore W4210251569C2780117679 @default.
• W4210251569 hasConceptScore W4210251569C2780898057 @default.
• W4210251569 hasConceptScore W4210251569C3006700255 @default.
• W4210251569 hasConceptScore W4210251569C3007834351 @default.
• W4210251569 hasConceptScore W4210251569C3008058167 @default.
• W4210251569 hasConceptScore W4210251569C41008148 @default.
• W4210251569 hasConceptScore W4210251569C524204448 @default.
• W4210251569 hasConceptScore W4210251569C71924100 @default.
• W4210251569 hasIssue "4" @default.
• W4210251569 hasLocation W42102515691 @default.
• W4210251569 hasLocation W42102515692 @default.
• W4210251569 hasOpenAccess W4210251569 @default.
• W4210251569 hasPrimaryLocation W42102515691 @default.
• W4210251569 hasRelatedWork W3011896036 @default.
• W4210251569 hasRelatedWork W3021484935 @default.
• W4210251569 hasRelatedWork W3031898936 @default.
• W4210251569 hasRelatedWork W3083031127 @default.
• W4210251569 hasRelatedWork W3087648734 @default.
• W4210251569 hasRelatedWork W3178186717 @default.
• W4210251569 hasRelatedWork W3184386184 @default.
• W4210251569 hasRelatedWork W4200039086 @default.
• W4210251569 hasRelatedWork W4206249207 @default.
• W4210251569 hasRelatedWork W4287374796 @default.
• W4210251569 hasVolume "35" @default.
• W4210251569 isParatext "false" @default.
• W4210251569 isRetracted "false" @default.
• W4210251569 workType "article" @default.